Press coverage about American Renal Associates Holdings (NYSE:ARA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. American Renal Associates Holdings earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.3453404846279 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

American Renal Associates Holdings (NYSE ARA) traded up 2.70% during mid-day trading on Friday, reaching $14.44. The company’s stock had a trading volume of 305,057 shares. American Renal Associates Holdings has a 1-year low of $13.74 and a 1-year high of $25.42. The company’s market capitalization is $451.76 million. The firm has a 50 day moving average price of $17.36 and a 200-day moving average price of $18.11.

American Renal Associates Holdings (NYSE:ARA) last issued its earnings results on Tuesday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.04. The business had revenue of $185.99 million for the quarter, compared to analysts’ expectations of $188.23 million. American Renal Associates Holdings had a positive return on equity of 18.25% and a negative net margin of 1.54%. American Renal Associates Holdings’s revenue was up .2% compared to the same quarter last year. On average, equities analysts predict that American Renal Associates Holdings will post $0.54 EPS for the current fiscal year.

A number of research analysts recently weighed in on the company. Zacks Investment Research lowered American Renal Associates Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Wells Fargo & Company raised American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday, May 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $25.50.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-american-renal-associates-holdings-ara-stock-price.html.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.